INTRODUCTION:
Patients undergoing open cranial vault remodeling for craniosynostosis frequently experience high blood loss and require transfusion. Although multiple strategies have been proposed, little consensus exists regarding best practices. [1] [2] [3] [4] We have developed a novel blood conservation protocol.
METHODS:
Forty-one consecutive patients undergoing open cranial vault remodeling were retrospectively reviewed. Early in the series, individual anesthesiologist preference dictated aminocaproic acid (ACA) use, and no patients received erythropoietin (EPO). After protocol initiation, all patients were evaluated for EPO and all patients received intraoperative ACA. Transfusion guidelines were defined. Cell Saver device was used when possible. Comparisons were made between the new protocol "ACA+EPO Group" (received ACA, received EPO), the pre-protocol "ACA Only Group" (received ACA, did not receive EPO), and the pre-protocol "No ACA Group" (did not receive ACA, did not receive EPO). Tukey's HSD Test was used to compare groups on patient characteristics, estimated blood loss (EBL), and allogeneic packed red blood cell transfusion volume.
RESULTS:
Age, weight, and surgery time were similar across all groups (p>0.05). Hemoglobin and hematocrit increased after EPO administration from 11.3/32.8 to 15.1/47.3 (p<0.05).
The ACA+EPO Group (n=9) had mean EBL of 11.7cc/kg (sd=10.4) and mean transfusion volume of 1.0cc/kg (sd=3.0). This group includes 8 patients (89%) not requiring transfusion intraoperatively and 6 patients (67%) discharged from the hospital transfusion-free. One patient (11%) received autologous transfusion from Cell Saver. The ACA Only Group (n=11) had mean EBL of 16.7cc/kg (sd=12.6) and mean transfusion volume of 17.1cc/kg (sd=23.1). This group includes 4 patients (36%) not requiring transfusion intraoperatively and 3 patients (27%) discharged from the hospital transfusion-free. Two patients (18%) received autologous transfusion from Cell Saver. The No ACA Group (n=21) had mean EBL of 44.7cc/kg (sd=24.1) and mean transfusion volume of 44.0cc/kg (sd=39.3). All patients required transfusion intraoperatively. Three patients (14%) received autologous transfusion from Cell Saver. The ACA+EPO Group had significantly lower EBL and transfusion volume compared to the No ACA Group (p<0.05). The ACA+EPO Group required less transfusion volume than the ACA only group, however this difference was not statistically significant (p>0.05).
CONCLUSION:
Our protocol emphasizing EPO and ACA decreases EBL and transfusion volume compared to a group not receiving ACA. Further data will be required to elucidate the efficacy of this protocol in reducing transfusion volume compared to an ACA only protocol.
